BUZZ-Ironwood rises after US sets Medicare price for constipation drug ** Shares of drugmaker Ironwood Pharmaceuticals' IRWD.O shares rise 1.3% to $3.17 premarket
** Co says U.S. Department of Health and Human Services has set the new Medicare price for co's Linzess at $136 for a 30-day supply
** Co's Linzess treats chronic constipation and irritable bowel syndrome with constipation - IRWD
** New price will apply from Jan. 1, 2027 under Inflation Reduction Act, co says
** Co says revised price aligns with its expectations
** Up to last close, stock down ~30% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments